<SUBMISSION>
<ACCESSION-NUMBER>0001047469-04-012095
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20040414
<ITEMS>5
<ITEMS>7
<FILING-DATE>20040415
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PHARMACOPEIA INC
<CIK>0001002388
<ASSIGNED-SIC>7372
<IRS-NUMBER>330557266
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-27188
<FILM-NUMBER>04735159
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>CN 5350
<CITY>PRINCETON
<STATE>NJ
<ZIP>08543-5350
<PHONE>6094523600
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>CN 5350
<CITY>PRINCETON
<STATE>NJ
<ZIP>08543-5350
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2133768z8-k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>FORM 8-K  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>CURRENT REPORT  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B> Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Date of Report (Date of earliest event reported): April&nbsp;14, 2004 </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>PHARMACOPEIA,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>(Exact name of registrant as specified in its charter)  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>Delaware</B></FONT><FONT SIZE=2><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>0-27118</B></FONT><FONT SIZE=2><BR>
(Commission<BR>
File Number)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="32%" ALIGN="CENTER"><FONT SIZE=2><B>33-0557266</B></FONT><FONT SIZE=2><BR>
(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>PO Box 5350, Princeton, New Jersey</B></FONT><FONT SIZE=2><BR>
(Address of principal executive offices)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>08543-5350</B></FONT><FONT SIZE=2><BR>
(Zip Code)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>(609)&nbsp;452-3600<BR>  </B></FONT><FONT SIZE=2>(Registrant's telephone number, including area code) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Not Applicable<BR>  </B></FONT><FONT SIZE=2>(Former name, former address and former fiscal year, if changed since last report) </FONT></P>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="1",CHK=1015104,FOLIO='blank',FILE='DISK043:[04SAN5.04SAN1165]BA1165A.;1',USER='JPATROW',CD='14-APR-2004;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><B>Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;14, 2004, Pharmacopeia,&nbsp;Inc. (the "Company") issued a press release announcing the declaration of a dividend of all the outstanding shares of common stock of
Pharmacopeia Drug Discovery,&nbsp;Inc., the drug discovery business being spun off by the Company. A copy of the Company's press release is furnished as an exhibit to this report. </FONT></P>

<P><FONT SIZE=2><B>Item 7. FINANCIAL STATEMENTS AND EXHIBITS  </B></FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Exhibits.
</FONT></DD></DL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="12%" ALIGN="LEFT"><FONT SIZE=1><B>Exhibit Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="85%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>99.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Press Release dated April 14, 2004</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>Signatures </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>PHARMACOPEIA,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>By:</FONT></TD>
<TD WIDTH="54%"><FONT SIZE=2>/s/ John J. Hanlon</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>John J. Hanlon, Executive Vice President and<BR>
Chief Financial Officer</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Date:
April&nbsp;15, 2004 </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="1",CHK=455818,FOLIO='blank',FILE='DISK043:[04SAN5.04SAN1165]DE1165A.;3',USER='JMILLER',CD='14-APR-2004;20:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=RKING,SEQ=,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a2133768zex-99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04SAN1165_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit&nbsp;99.1  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kg1165_pharmacopeia_declares_dividend__pha03126"> </A>
<A NAME="toc_kg1165_1"> </A>
<BR></FONT><FONT SIZE=2><B>PHARMACOPEIA DECLARES DIVIDEND TO EFFECT SPIN-OFF OF<BR>  PHARMACOPEIA DRUG DISCOVERY    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Princeton, New Jersey, April&nbsp;14, 2004&#151;Pharmacopeia,&nbsp;Inc. (Nasdaq: ACCL) today announced that its Board of Directors declared a dividend
of all of the outstanding shares of common stock of Pharmacopeia Drug Discovery,&nbsp;Inc. (PDD), the drug discovery business being spun off by Pharmacopeia. The dividend will be distributed to
Pharmacopeia stockholders at the ratio of one share of PDD common stock for every two shares of Pharmacopeia common stock held. The dividend is expected to be payable on April&nbsp;30, 2004 to
Pharmacopeia stockholders of record as of the close of business on April&nbsp;16, 2004. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
actual number of shares of Pharmacopeia Drug Discovery common stock to be distributed will be based on the number of shares of Pharmacopeia common stock outstanding as of the close
of business on April&nbsp;16, 2004. Fractional shares will not be distributed but will be aggregated and sold in the public market. The net cash proceeds of these sales will be distributed ratably
to those stockholders who would have otherwise received fractional shares. Since the dividend will be paid in book-entry form, physical stock certificates will be issued only upon request. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
dividend is intended to qualify as a tax-free distribution to Pharmacopeia stockholders for U.S. federal income tax purposes (except for cash received in lieu of any
fractional share interest). Payment of the dividend is subject to the satisfaction or waiver of certain conditions, including Pharmacopeia's receiving an opinion of counsel regarding the
tax-free nature of the distribution, as well as Pharmacopeia Drug Discovery's registration statement on Form&nbsp;10 being declared effective by the Securities and Exchange Commission. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacopeia
Drug Discovery has filed an application to list shares of its common stock on The Nasdaq National Market under the symbol "PCOP" upon the completion of the
spin-off. Pharmacopeia will continue to trade under the symbol "ACCL" after the distribution and, subject to stockholder approval at its upcoming annual meeting, the company
will change its name to "Accelrys,&nbsp;Inc." to better reflect its focus on the software business. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacopeia
(www.pharmacopeia.com) is a leader in enabling science and technology that accelerates and improves the drug discovery and chemical development processes. Pharmacopeia's
Drug Discovery
business integrates proprietary small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods and informatics to
discover and optimize lead compounds. Pharmacopeia's software subsidiary, Accelrys, develops and commercializes molecular modeling and simulation software for the life sciences and materials research
markets, cheminformatics and decision support systems, and bioinformatics tools including gene sequence analysis. Pharmacopeia is headquartered in Princeton, New Jersey. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>###
</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="2",CHK=257110,FOLIO='blank',FILE='DISK043:[04SAN5.04SAN1165]KG1165A.;4',USER='JMILLER',CD='14-APR-2004;20:35' -->

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>When used anywhere in this document, the words "expects", "believes", "anticipates", "estimates" and similar expressions are intended to identify forward-looking
statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its
current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the
acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, completion of
the spin-off of PDD and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on
Form&nbsp;10-K and subsequent reports on Form&nbsp;10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in
this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this
document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained
herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.</I></FONT></P>

<P><FONT SIZE=2>Contact:<BR>
John J. Hanlon<BR>
Chief Financial Officer<BR>
Pharmacopeia, Inc.<BR>
(609) 452-3600<BR>
irreq@pharmacopeia.com<BR></FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="2",CHK=899170,FOLIO='blank',FILE='DISK043:[04SAN5.04SAN1165]KG1165A.;4',USER='JMILLER',CD='14-APR-2004;20:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04SAN1165_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_kg1165_1">PHARMACOPEIA DECLARES DIVIDEND TO EFFECT SPIN-OFF OF PHARMACOPEIA DRUG DISCOVERY</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=RKING,SEQ=,EFW="2133768",CP="PHARMACOPEIA, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
